First-in-human immunotherapy study for advanced solid tumors
Part of Cancer, Lungs & breathing, Skin clinical trials.
This Phase 1 trial tests SYNC-T, an immunotherapy, in people with advanced or metastatic solid cancers. It aims to find the safest dose and see whether the treatment can shrink or control tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can sign informed consent and follow study visits
- You have an advanced or metastatic solid tumor that has not responded to standard treatment, or no standard option exists
- You must have had a recent heart check and been cleared for treatment
- Your recent cancer side effects must mostly be gone (to mild or baseline, except hair loss)
- Your blood counts, kidney, and liver tests must meet required minimum levels
- You need at least one tumor spot that can be seen on scan and is reachable for injection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy (HS-IT101) for people with advanced solid tumors that have not responded to standard treatments. It uses immune cells from your own tumor to fight cancer, and researchers want to see if it is safe and effective.
This trial tests a new drug called PTX-912 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It is a first-in-human study, meaning this is the first time PTX-912 is being given to people, to see how safe it is and how well it works.
This early-phase study tests a treatment made from your own tumor-fighting immune cells (TIL cells) for advanced solid cancers that have worsened or no longer respond to standard therapy. The main goal is to learn whether it is safe and whether it can shrink tumors for people who have limited options.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
This trial tests a new drug called AT1019 given together with targeted radiation (SBRT) and an immunotherapy drug for people with advanced solid tumors that are already being treated with immunotherapy. It aims to see if this combination can shrink or control tumors better.
This study tests a new treatment that takes immune cells from a small piece of your tumor, grows them in a lab, and then puts them back into your body to fight the cancer. It is for people with advanced lung, cervical, or breast cancer who have already tried standard treatments.
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.